Randomized, double-blind, clinical trial of a polyvalent melanoma vaccine in patients with stage III melanoma.

被引：0
|
作者：
Bystryn, JC
Oratz, R
Shapiro, R
Harris, M
Roses, D
Jacquotte, A
机构：
[1] Kaplan Comprehens Canc Ctr, New York, NY USA
[2] NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA
[3] NYU, Sch Med, Dept Med, New York, NY USA
[4] NYU, Sch Med, Dept Surg, New York, NY USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1998年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：498 / 498
页数：1
相关论文
共 50 条
  • [31] Phase 2 trial of talabostat in stage IV melanoma.
    Redman, BG
    Ernstoff, MS
    Gajewski, TF
    Cunningham, C
    Lawson, DH
    Gregoire, L
    Haltom, E
    Uprichard, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 727S - 727S
  • [32] Queensland, Australia randomized trial of population screening for melanoma.
    Aitken, J
    Elwood, M
    Lowe, J
    Firman, D
    Balanda, K
    Ring, I
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1173S - 1173S
  • [33] Adjuavnt tyrosinase peptide vaccination in patients with resected stage III/IV melanoma.
    Letsch, A.
    Scheibenbogen, C.
    Fluck, M.
    Asemissen, A.
    Nagorsen, D.
    Thiel, E.
    Keilholz, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 117S - 117S
  • [34] Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.
    Guo, Jun
    Cui, Chuan Liang
    Gu, Kangsheng
    Tao, Min
    Xin, Song
    Lin, Tongyu
    Ren, Xiu Bao
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma.
    Riker, A. I.
    Alsfeld, L. C.
    Harrison, M.
    Foxworth, D.
    Lee, Q.
    Rossi, G. R.
    Tennant, L.
    Ramsey, W. J.
    Vahanian, N. N.
    Link, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma
    Hodi, F. S.
    O'Day, S.
    McDermott, D. F.
    Haanen, J. B.
    Robert, C.
    Zhu, X.
    Yellin, M. J.
    Ibrahim, R. A.
    Hoos, A.
    Wolchok, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] Treatment of patients with inoperable stage III or stage IV melanoma. Societe francaise de dermatologie
    Guillot, B.
    Charles, J.
    Jeudy, G.
    Cupissol, D.
    Dupuy, A.
    Dutriaux, C.
    Gangloff, D.
    Magne, N.
    Mirabe, X.
    M'Sadek, A.
    Pracht, M.
    Sichel, C.
    Do Outeiro, G.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (6-7): : 413 - 422
  • [38] A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma.
    Albertini, Mark R.
    Ranheim, Erik
    Hank, Jacquelyn A.
    Zuleger, Cindy
    McFarland, Thomas
    Collins, Jennifer
    Clements, Erin
    Weber, Sharon M.
    Weigel, Tracey
    Neuman, Heather B.
    Hartig, Gregory K.
    Mahvi, David
    Henry, MaryBeth
    Gan, Jacek
    Yang, Richard
    Kim, KyungMann
    Gillies, Stephen
    Sondel, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial
    Pakfetrat, Maryam
    Basiri, Fatemeh
    Malekmakan, Leila
    Roozbeh, Jamshid
    JOURNAL OF NEPHROLOGY, 2014, 27 (02) : 203 - 207
  • [40] Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial
    Maryam Pakfetrat
    Fatemeh Basiri
    Leila Malekmakan
    Jamshid Roozbeh
    Journal of Nephrology, 2014, 27 : 203 - 207
12345